TAK - Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

• After edasalonexent's failure last year, Catabasis Pharmaceuticals pivoted to the HAE market through the acquisition of Quellis Biosciences.
• The acquisition brought QLS-215, a preclinical stage monoclonal antibody with a potentially improved profile compared to prophylactic market leader Takhzyro.
• Much longer half-life and increased potency could result in less frequent administration and it could also improve efficacy.
• The HAE market is increasingly competitive with additional promising therapies in development, but if preclinical data of QLS-215 translate well into humans, Catabasis could deliver significant gains in the following years.

For further details see: